Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany
Nilemdo 180 mg film-coated tablets.
Pharmaceutical Form |
---|
Film-coated tablet. White to off-white, oval, film-coated tablet of approximately 13.97 mm × 6.60 mm × 4.80 mm debossed with “180” on one side and “ESP” on the other side. |
Each film-coated tablet contains 180 mg of bempedoic acid.
Excipient(s) with known effect: Each 180 mg film-coated tablet contains 28.5 mg of lactose.
For the full list of excipients, see section 6.1.
Active Ingredient | Description | |
---|---|---|
Bempedoic acid |
Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. |
List of Excipients |
---|
Tablet core: Lactose monohydrate Film-coating: Partially hydrolysed poly(vinyl alcohol) (E1203) |
Polyvinyl chloride (PVC)/aluminum blisters.
Pack sizes of 10, 28, 30, 90, 98, or 100 film-coated tablets.
Not all pack sizes may be marketed.
Daiichi Sankyo Europe GmbH, Zielstattstrasse 48, 81379 Munich, Germany
EU/1/20/1425
Date of first authorisation: 01/04/2020
Drug | Countries | |
---|---|---|
NILEMDO | Austria, Estonia, Ireland, Lithuania, Poland, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.